The value of functional genomics: a contingent valuation
Expert Review of Pharmacoeconomics & Outcomes Research · 07.02.2026 · 26 (2) · 195-202
DOI: 10.1080/14737167.2025.2605152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 23.12.2025. Verfasst von Francisco Santos Gonzalez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Economics of Genomics and Precision Medicine Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourn…. Hauptthemen laut MEDLINE: Genomics, Rare Diseases, Genetic Testing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Australian Commonwealth Government, University of Melbourne, Australian Undiagnosed Diseases Network.
Abstract (Originalsprache)
BACKGROUND: Functional genomics approaches, such as transcriptomics and proteomics, can provide valuable insights into rare diseases when genomic sequencing fails to yield informative findings. This study estimated the monetary value that parents, carers and individuals with undiagnosed rare diseases place on functional genomics testing. RESEARCH DESIGN AND METHODS: A triple-bounded dichotomous choice contingent valuation survey was completed by carers and individuals with suspected rare monogenic disorders recruited as part of the Australian Undiagnosed Disease Network. A multilevel interval regression model was used to analyze response data and estimate the monetary value of functional genomics, in terms of willingness to pay (WTP). RESULTS: There was a total of 57 respondents (48%), primarily carers (95%). The mean WTP for functional genomics testing was estimated to be $2,522 (95% CI: $817-$4,228) [US $1,568 (95% CI: $508-$2,629)]. CONCLUSIONS: Our findings indicate that individuals with undiagnosed rare diseases and their parents or caregivers place high value on functional genomics testing. The estimated WTP is comparable to findings from contingent valuation studies of other genomic interventions and exceeds the expected economic cost of proteomics testing. These insights can inform a preference-based evaluation of the diagnostic outcomes and net benefits achieved through functional genomics, thereby guiding decision-making and clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Economics of Genomics and Precision Medicine Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
- Genomic Medicine Group, Murdoch Children's Research Institute, Melbourne, Australia.
- Australian Genomics, Melbourne, Australia.
- Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Förderung
- Australian Commonwealth Government
- University of Melbourne
- Australian Undiagnosed Diseases Network
- Australian Government’s Medical Research Future Fund
- Australian Genomics
- The Centre for Population Genomics
- Medical Research Future Fund (MRFF) Genomics Health Futures Mission grant
- Murdoch Children’s Research Institute
Zitieren
APA
Santos Gonzalez, F., Martin, E., Harris, M., Casauria, S., Udn-Aus, T. A. U. D. N., Christodoulou, J., & Goranitis, I. (2026). The value of functional genomics: a contingent valuation. Expert Review of Pharmacoeconomics & Outcomes Research, 26(2), 195-202. https://doi.org/10.1080/14737167.2025.2605152
Vancouver
Santos Gonzalez F, Martin E, Harris M, Casauria S, Udn-Aus TAUDN, Christodoulou J, et al. The value of functional genomics: a contingent valuation. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(2):195-202. doi:10.1080/14737167.2025.2605152
BibTeX
@article{SantosGonzalez2026,
author = {Santos Gonzalez, Francisco and Martin, Ellenore and Harris, Madeleine and Casauria, Sarah and Udn-Aus, The Australian Undiagnosed Diseases Network and Christodoulou, John and Goranitis, Ilias},
title = {The value of functional genomics: a contingent valuation},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {2},
pages = {195--202},
doi = {10.1080/14737167.2025.2605152}
}
EUVIMED